Abstract
An accurate, precise, simple and selective stability-indicating gradient reverse phase ultra performance liquid chromatographic method has been developed and validated for the quantitative determination of rupatadine and montelukast in pharmaceutical formulation in presence of degradation products. The chromatographic separation was performed on Acquity BEH C8 column (100 mm x 2.1 mm I.D., 1.7 μm) by using mobile phase containing a gradient mixture of solvent A (0.02 M KH2PO4, pH 3.0) and B (90:10 v/v mixture of acetonitrile and water) at flow rate of 0.5 mL/min. The detection was carried out at a wavelength of 240 nm. To establish stability indicating capability of the method, drug product was subjected to the stress conditions of acid, base, oxidative, hydrolytic, thermal and photolytic degradation. The degradation products were well resolved from rupatadine and montelukast. The developed method was validated as per ICH guidelines with respect to specificity, linearity, accuracy, precision and robustness.
Keywords: Degradation, Development, Stability-indicating, Montelukast, rupatadine, UPLC-UV, Validation, rupatadine, Acquity BEH, hydrolytic
Related Journals
Related Books
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Postbiotics: Science, Technology and Applications
Biologically Active Natural Products from Asia and Africa: A Selection of Topics
32